RAP2A and prostate carcinoma: Upregulation of RAP2A has been observed in several human malignancies such as follicular thyroid cancer (Prabakaran et al., 2011), prostate cancer (Bigler et al., 2007), renal cancer (Wu et al., 2017), gastric cancer (Zhang J. et al., 2020) and bladder cancer (Wang et al., 2020).